Evidence map›Paper›PMID 27379231›Full record

ReviewFrontiers in bioengineering and biotechnology2016

Upconversion Nanoparticles for Bioimaging and Regenerative Medicine.

María González-Béjar, Laura Francés-Soriano, Julia Pérez-Prieto

Abstract readReview
In one paragraph

Review in Frontiers in bioengineering and biotechnology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed.

  1. Review
  2. Review
  3. Article
  4. Review
  5. Article
  6. Bioimaging with Upconversion Nanoparticles.Advanced photonics research · 2022
    Article
  7. Review
  8. Review
  9. Article
  10. Review
  11. Article
  12. Review
  13. NIR-II Upconversion Photoluminescence of ErFrontiers in chemistry · 2021
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

María González-BéjarDepartamento de Química Orgánica, Instituto de Ciencia Molecular (ICMol), Universidad de Valencia , Valencia , Spain.
Laura Francés-SorianoDepartamento de Química Orgánica, Instituto de Ciencia Molecular (ICMol), Universidad de Valencia , Valencia , Spain.
Julia Pérez-PrietoDepartamento de Química Orgánica, Instituto de Ciencia Molecular (ICMol), Universidad de Valencia , Valencia , Spain.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nanomaterials are proving useful for regenerative medicine in combination with stem cell therapy. Nanoparticles (NPs) can be administrated and targeted to desired tissues or organs and subsequently be used in non-invasive real-time visualization and tracking of cells by means of different imaging techniques, can act as therapeutic agent nanocarriers, and can also serve as scaffolds to guide the growth of new tissue. NPs can be of different chemical nature, such as gold, iron oxide, cadmium selenide, and carbon, and have the potential to be used in regenerative medicine. However, there are still many issues to be solved, such as toxicity, stability, and resident time. Upconversion NPs have relevant properties such as (i) low toxicity, (ii) capability to absorb light in an optical region where absorption in tissues is minimal and penetration is optimal (note they can also be designed to emit in the near-infrared region), and (iii) they can be used in multiplexing and multimodal imaging. An overview on the potentiality of upconversion materials in regenerative medicine is given.

Indexed as

cell behavior regulationmulti-wavelength/multimodal bioimagingNIR excitationnon-toxic nanoparticlestransparencyupconverted (UV–VIS–NIR) emission

Identifiers

PMID27379231
PMCPMC4904131

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.